Brodowicz, T
Lang, I
Kahan, Z
Greil, R
Beslija, S
Stemmer, S M
Kaufman, B
Petruzelka, L
Eniu, A
Anghel, R
Koynov, K
Vrbanec, D
Pienkowski, T
Melichar, B
Spanik, S
Ahlers, S
Messinger, D
Inbar, M J
Zielinski, C
Article History
Received: 8 May 2014
Revised: 4 August 2014
Accepted: 18 August 2014
First Online: 30 September 2014
Competing interests
: Speaker honoraria: TB (Roche), RG (Roche), AE (Roche), KK (AstraZeneca, Roche, Merck Serono, Eli Lilly, sanofi-aventis, GlaxoSmithKline and Novartis Research), BM (Roche, Eli Lilly, Novartis, AstraZeneca and GlaxoSmithKline), CZ (Roche, Eli Lilly and Pfizer); Research support: RG (Roche); Advisor: KK (Boehringer Ingelheim, Roche and Eli Lily), BM (Roche and Merck Serono); Employment: SA (IST GmbH), DM (IST GmbH; IST GmbH is the clinical research organisation providing consultancy and various other services to Roche and the Central European Cooperative Oncology Group). All other authors declare no conflict of interest.